Core Insights - SCYNEXIS, Inc. reported financial results for Q2 2025, highlighting progress in its drug development pipeline and ongoing disputes with GSK regarding milestone payments [1][5][9]. Drug Development Progress - The company is advancing its second-generation fungicide candidate, SCY-247, with Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) data expected to be announced in Q3 2025 [2][7]. - Positive preclinical efficacy data for SCY-247 was presented at the ESCMID meeting, showcasing its potential against difficult-to-treat fungal infections [4]. - The first new patient was dosed in the Phase 3 MARIO study after the FDA lifted the clinical hold, triggering a $10 million milestone payment from GSK [5][6]. Financial Performance - For Q2 2025, SCYNEXIS reported revenue of $1.4 million, up from $0.7 million in Q2 2024, primarily from the GSK License Agreement [9]. - Research and development expenses increased to $7.1 million in Q2 2025 from $6.8 million in Q2 2024, driven by higher costs in chemistry, manufacturing, and controls [10]. - Selling, general, and administrative expenses rose to $3.8 million in Q2 2025, a 20% increase from $3.2 million in Q2 2024, mainly due to higher professional fees [11]. - The net loss for Q2 2025 was $6.9 million, or $(0.14) per share, compared to a net loss of $14.5 million, or $(0.30) per share in Q2 2024 [13]. Cash Position - As of June 30, 2025, the company had cash, cash equivalents, and investments totaling $46.5 million, down from $75.1 million at the end of 2024, providing a cash runway into Q4 2026 [14]. Legal Developments - The U.S. District Court granted SCYNEXIS's motion to dismiss a securities class action lawsuit filed in November 2023, allowing the plaintiff to amend the complaint within 30 days [8]. Corporate Strategy - SCYNEXIS is working to transfer the New Drug Application for Brexafemme to GSK by the end of 2025, enabling GSK to initiate regulatory discussions for the product's relaunch [6][16].